Chemomab obtained feedback from two recent FDA meetings on nebokitug

Chemomab Therapeutics (CMMB) reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program. As part of the FDA End-of-Phase 2, EOP2, review process, Chemomab and the FDA addressed multiple Chemistry, Manufacturing, and Controls, CMC, topics critical to ensuring the quality and consistency of drug supply for the late-stage development and eventual commercialization of nebokitug. Following productive discussions, the FDA indicated agreement with the CMC strategy proposed by Chemomab and its contract manufacturing partner.